Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
Authors
Keywords
Biomarker, Cancer, DNA damage response, DNA repair, Immunotherapy, Genomic instability, Tumor microenvironment, PD-1, PD-L1, cGAS–STING, DDR
Journal
Acta Pharmaceutica Sinica B
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-01-10
DOI
10.1016/j.apsb.2021.01.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development
- (2020) Carlos R. Figueiredo et al. JOURNAL OF PATHOLOGY
- DNA-repair enzyme turns to translation
- (2020) Alan J. Warren NATURE
- Manganese-Based Nanoactivator Optimizes Cancer Immunotherapy via Enhancing Innate Immunity
- (2020) Lin Hou et al. ACS Nano
- Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes
- (2020) Jennifer L. Beebe-Dimmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker-Guided Development of DNA Repair Inhibitors
- (2020) James M. Cleary et al. MOLECULAR CELL
- Mechanisms and therapeutic implications of hypermutation in gliomas
- (2020) Mehdi Touat et al. NATURE
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- (2020) Anniina Färkkilä et al. Nature Communications
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer
- (2020) Silvia Tabano et al. Cancers
- cGAS-STING, an important pathway in cancer immunotherapy
- (2020) Minlin Jiang et al. Journal of Hematology & Oncology
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity
- (2019) Anne Margriet Heijink et al. Nature Communications
- BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
- (2019) Raunak Shrestha et al. Genome Medicine
- Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
- (2019) Marc Ladanyi et al. Genome Medicine
- Base excision repair regulates PD-L1 expression in cancer cells
- (2019) Tiara Bunga Mayang Permata et al. ONCOGENE
- ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment
- (2019) Magnus T. Dillon et al. CLINICAL CANCER RESEARCH
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition
- (2019) Priya Patel et al. OncoImmunology
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes
- (2019) Thiago Vidotto et al. Journal for ImmunoTherapy of Cancer
- Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
- (2019) Xi Chen et al. Acta Pharmaceutica Sinica B
- Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells
- (2019) Baoyuan Zhang et al. Acta Pharmaceutica Sinica B
- Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker
- (2019) Heejung Chae et al. EUROPEAN JOURNAL OF CANCER
- STING: a master regulator in the cancer-immunity cycle
- (2019) Yuanyuan Zhu et al. Molecular Cancer
- Pan-Cancer Analysis of Potential Synthetic Lethal Drug Targets Specific to Alterations in DNA Damage Response
- (2019) Shaoli Das et al. Frontiers in Oncology
- Pembrolizumab treatment of a patient with xeroderma pigmentosum with disseminated melanoma and multiple nonmelanoma skin cancers
- (2018) K.H. Kraemer et al. BRITISH JOURNAL OF DERMATOLOGY
- DNA Repair Deficiency and Immunotherapy Response
- (2018) Kent W. Mouw et al. JOURNAL OF CLINICAL ONCOLOGY
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the replication stress response in cancer
- (2018) Josep V. Forment et al. PHARMACOLOGY & THERAPEUTICS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Co-mutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade
- (2018) Jie Wang et al. CANCER RESEARCH
- ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation
- (2018) Frank P. Vendetti et al. JOURNAL OF CLINICAL INVESTIGATION
- KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
- (2018) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
- (2018) Daniel Nava Rodrigues et al. JOURNAL OF CLINICAL INVESTIGATION
- Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab
- (2017) Axel Hauschild et al. EUROPEAN JOURNAL OF CANCER
- Rationale for stimulator of interferon genes–targeted cancer immunotherapy
- (2017) Thaiz Rivera Vargas et al. EUROPEAN JOURNAL OF CANCER
- LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
- (2017) Yayi He et al. Journal of Thoracic Oncology
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
- (2017) Giovanni Germano et al. NATURE
- A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
- (2017) Paz Polak et al. NATURE GENETICS
- Dramatic response to nivolumab in xeroderma pigmentosum skin tumor
- (2017) Fanny Chambon et al. PEDIATRIC BLOOD & CANCER
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
- (2017) Teresa Davoli et al. SCIENCE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- (2017) Kent W. Mouw et al. Cancer Discovery
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- The role of neoantigens in response to immune checkpoint blockade
- (2016) Nadeem Riaz et al. INTERNATIONAL IMMUNOLOGY
- Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
- (2016) Janice M. Mehnert et al. JOURNAL OF CLINICAL INVESTIGATION
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Influence of Ku86 and XRCC4 expression in uterine cervical cancer on the response to preoperative radiotherapy
- (2016) Yu Takada et al. Medical Molecular Morphology
- Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
- (2016) Qi Chen et al. NATURE IMMUNOLOGY
- Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored
- (2016) Stephen K.H. Li et al. TRENDS IN MOLECULAR MEDICINE
- Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents
- (2016) Julie Gaston et al. Oncotarget
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer
- (2015) Jing Huang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- DNA excision repair at telomeres
- (2015) Pingping Jia et al. DNA REPAIR
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- Mechanisms of genome instability induced by RNA-processing defects
- (2014) Yujia A. Chan et al. TRENDS IN GENETICS
- Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesions--Response
- (2013) G. Chene et al. CLINICAL CANCER RESEARCH
- Replication stress links structural and numerical cancer chromosomal instability
- (2013) Rebecca A. Burrell et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
- (2013) W. Joost Lesterhuis et al. PLoS One
- Postreplicative Mismatch Repair
- (2013) J. Jiricny Cold Spring Harbor Perspectives in Biology
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The DNA Damage Response Induces IFN
- (2011) Sabrina Brzostek-Racine et al. JOURNAL OF IMMUNOLOGY
- Mutation of NIMA-related kinase 1 (NEK1) leads to chromosome instability
- (2011) Yumay Chen et al. Molecular Cancer
- Homologous recombination in cancer development, treatment and development of drug resistance
- (2010) T. Helleday CARCINOGENESIS
- Mechanism of Eukaryotic Homologous Recombination
- (2008) Joseph San Filippo et al. Annual Review of Biochemistry
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search